FY2025 Earnings Estimate for SAGE Issued By Leerink Partnrs

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Investment analysts at Leerink Partnrs reduced their FY2025 earnings per share (EPS) estimates for shares of Sage Therapeutics in a report released on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will post earnings of ($3.05) per share for the year, down from their prior forecast of ($2.95). The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.46) per share. Leerink Partnrs also issued estimates for Sage Therapeutics’ FY2026 earnings at ($1.30) EPS, FY2027 earnings at ($1.64) EPS and FY2028 earnings at ($1.40) EPS.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) EPS for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). The business had revenue of $11.87 million for the quarter, compared to analysts’ expectations of $10.80 million. Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. The company’s revenue for the quarter was up 337.1% on a year-over-year basis. During the same period last year, the business posted ($2.81) EPS.

A number of other equities research analysts also recently weighed in on SAGE. Bank of America dropped their price objective on Sage Therapeutics from $11.00 to $6.00 and set an “underperform” rating on the stock in a research report on Wednesday, October 9th. TD Cowen decreased their target price on shares of Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Thursday, November 21st. StockNews.com downgraded Sage Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Piper Sandler decreased their price target on Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, January 2nd. Finally, Stifel Nicolaus dropped their price target on Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating on the stock in a research note on Monday, December 16th. Three investment analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.53.

Sage Therapeutics Trading Down 1.4 %

Shares of NASDAQ SAGE opened at $7.25 on Friday. Sage Therapeutics has a 12-month low of $4.62 and a 12-month high of $27.39. The stock’s fifty day simple moving average is $6.07 and its two-hundred day simple moving average is $7.22. The stock has a market capitalization of $443.48 million, a PE ratio of -1.30 and a beta of 0.91.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. lifted its holdings in Sage Therapeutics by 66.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 4,672 shares in the last quarter. Creative Planning acquired a new stake in shares of Sage Therapeutics in the third quarter valued at about $88,000. Empowered Funds LLC purchased a new position in shares of Sage Therapeutics in the fourth quarter worth about $91,000. SG Americas Securities LLC grew its position in shares of Sage Therapeutics by 57.7% in the fourth quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 8,228 shares in the last quarter. Finally, Quest Partners LLC increased its stake in shares of Sage Therapeutics by 56.3% in the 3rd quarter. Quest Partners LLC now owns 18,381 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 6,618 shares during the last quarter. 99.22% of the stock is owned by institutional investors and hedge funds.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.